- Gene therapy concern Solid Biosciences looks to be taking a meaningful step forward in its Phase 1/2 Duchenne muscular dystrophy trial, after dosing only seven patients in 3 1/2 years.
- Although Sarepta Therapeutics (SRPT) suffered a setback with its therapy in January 2021, Pfizer’s (PFE) Duchenne gene therapy candidate is far ahead, undergoing Phase 3 evaluation.
- With a seemingly low bar for approval, solid institutional investor participation on its March 2021 secondary, and a collaboration inked in October 2020, this Busted IPO merited a deeper dive.
- A full analysis follows in the paragraphs below.
For further details see:
Solid Biosciences: Future More Uncertain Than Solid